48 / 56
KEYNOTE 059 Cohort 2
1
st
Line, Chemo + Pembro
a
Only patients with measurable disease per RECIST v1.1 by central review at baseline who had ≥1 postbaseline assessment were included (n = 25); assessment was nonevaluable for 1 patient.
b
Longitudinal change in the sum of the longest target lesion diameters from baseline in patients with ≥1 postbaseline assessment (n = 25).
+No progressive disease at last disease assessment.
Data cutoff: April 21, 2017.
24 patients (96%) experienced a reduction in
target lesion size
–100
–80
–60
–40
–20
0
20
Change From Baseline, %
PD-L1 positive
PD-L1 expression unknown
PD-L1 negative
0 2 4 6 8 10 12 14 16 18 20 22 24
–100
–75
–50
–25
0
25
50
Change From Baseline, %
On-treatment responder
Discontinued responder
On-treatment nonresponder
Discontinued nonresponder
Time Since Treatment Initiation, months
Median (range) duration of response:
4.6 (2.6-20.3+) months
Best Percentage Change in All Patients (n = 24)
a
Longitudinal Change in All Patients (n = 25)
b
ORR
60% (all)
69% (PD-L1 pos)
Kang ESMO GI 2017